Showing results (1011-1020 of 1,047) with videos related to

Sort By:
Pageof 105
Frontiers in Immunology|April 17, 2023
Characterisation of the pro-inflammatory cytokine signature in severe COVID-19Heike C Hawerkamp, Adam H Dyer, Neha D Patil, et al.
Transplantation|September 16, 2015
The Dutch Transplantation in Vasculitis (DUTRAVAS) Study: Outcome of Renal Transplantation in Antineutrophil Cytoplasmic Antibody-associated GlomerulonephritisArda Göçeroğlu, Chinar Rahmattulla, Annelies E Berden, et al.
Plos One|July 3, 2014
Risk factors for death in 632 patients with sickle cell disease in the United States and United KingdomMark T Gladwin, Robyn J Barst, J Simon R Gibbs, et al.
The Journal of Rheumatology|January 15, 2023
Traditional and Disease-Specific Risk Factors for Cardiovascular Events in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multinational Retrospective StudySergey Moiseev, Nikolay Bulanov, Matija Crnogorac, et al.
Blood|April 30, 2011
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacityRoberto F Machado, Robyn J Barst, Nancy A Yovetich, et al.
American Journal of Respiratory and Critical Care Medicine|June 26, 2020
International Consensus on ANCA Testing in Eosinophilic Granulomatosis with PolyangiitisSergey Moiseev, Xavier Bossuyt, Yoshihiro Arimura, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 30, 2016
Technology in Parkinson's disease: Challenges and opportunitiesAlberto J Espay, Paolo Bonato, Fatta B Nahab, et al.
Frontiers in Aging Neuroscience|November 2, 2020
Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP)Andrea Sturchio, Luca Marsili, Joaquin A Vizcarra, et al.
Annals of the Rheumatic Diseases|March 17, 2023
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 updateBernhard Hellmich, Beatriz Sanchez-Alamo, Jan H Schirmer, et al.
Nature Communications|November 9, 2018
Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancerGordon C Jayson, Cong Zhou, Alison Backen, et al.
Pageof 105